OneSource Specialty Pharma ties up with Germany’s Formycon for Biosimilar manufacturing
Under the agreement, OneSource will provide integrated Drug Substance and Drug Product manufacturing for Formycon’s biosimilar programs from its biologics facility in Bangalore
Read the full articleYou might also wanna read
ONESOURCE Specialty Pharma Signs Strategic Manufacturing Deal With Formycon AG For 5 Global Biosimilars
ONESOURCE Specialty Pharma partners with Formycon AG for global biosimilar manufacturing, boosting its CDMO order book and validating its la
Europe–US new drug manufacturing outsourcing gap widens, reveals GlobalData
Contract manufacturing facilities located in the US and Europe provide biopharma companies with strategic options to diversify supply chains
Biocon Gains EMA Nod for Malaysia Insulin Line; European Supplies from Q2FY27
Biocon's Malaysian subsidiary has secured EMA approval for its new insulin glargine fill-finish line, with supplies to Europe projected to c
Biosimilars new trend after generics: Track these stocks for the next big story in pharma
The Indian pharma industry is now placing a major bet on biosimilars, which is hotting up after generics. With the expiration of patents on
Rationalizing Biological Drug Development: Biosimilar Science, Modality-Specific Pathways, and the Bioprocessing Revolution, Part 1
Regulatory frameworks for biosimilars were developed two decades ago to address the novelty of recombinant-protein products and genuine unce
GC Biopharma, Cytiva Deepen Supply Chain Ties for Alyglo Ingredients
GC Biopharma and Cytiva signed an MOU to build a priority supply system for Alyglo's core consumables and expand cooperation on mRNA and cel
Comments
Sign in to join the conversation.
No comments yet. Be the first.